Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Recommendation of “Moderate Buy” by Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has been given a consensus rating of “Moderate Buy” by the fifteen ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $209.4615.

A number of analysts have commented on CRL shares. Argus set a $200.00 target price on Charles River Laboratories International in a report on Monday, November 17th. Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price on the stock in a research note on Monday, December 15th. Mizuho set a $215.00 price target on shares of Charles River Laboratories International in a report on Friday, January 9th. Morgan Stanley set a $185.00 price objective on shares of Charles River Laboratories International in a report on Monday, December 1st. Finally, Barclays raised their target price on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, December 15th.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $161.15 on Tuesday. The business has a fifty day moving average price of $202.74 and a 200-day moving average price of $179.65. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. The company has a market capitalization of $7.93 billion, a PE ratio of -103.30, a PEG ratio of 4.88 and a beta of 1.63. Charles River Laboratories International has a 1-year low of $91.86 and a 1-year high of $228.88.

Hedge Funds Weigh In On Charles River Laboratories International

A number of institutional investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp raised its stake in shares of Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after buying an additional 1,074 shares during the period. Empowered Funds LLC bought a new position in shares of Charles River Laboratories International during the 1st quarter valued at approximately $418,000. CWM LLC increased its holdings in Charles River Laboratories International by 89.2% in the 2nd quarter. CWM LLC now owns 2,602 shares of the medical research company’s stock worth $395,000 after acquiring an additional 1,227 shares in the last quarter. Sequoia Financial Advisors LLC raised its stake in Charles River Laboratories International by 95.6% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 3,432 shares of the medical research company’s stock worth $521,000 after acquiring an additional 1,677 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Charles River Laboratories International during the second quarter valued at approximately $1,897,000. 98.91% of the stock is owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.